A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

Sponsor
Eli Lilly and Company
Study ID
NCT07073170
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3549492 — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.

Key Dates

Start date
Jul 25, 2025
Status verified
Mar 2026
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3549492 Dose 1
    Participants will receive LY3549492 orally
  • Experimental: LY3549492 Dose 2
    Participants will receive LY3549492 orally
  • Experimental: LY3549492 Dose 3
    Participants will receive LY3549492 orally
  • Placebo Comparator: Placebo
    Participants will receive Placebo orally

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Week 14 ]

Related Studies